NCT02329639Completed
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy
Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS)
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
Metastatic Breast cancer (MBC) patients from ten Italian Divisions of Medical Oncology, with histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15, every 4 weeks, will be enrolled for the present pharmacogenetic study. MBC patients treated with first-line chemotherapy including paclitaxel without bevacizumab will be also enrolled as control group.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 307 (actual)
- First submitted
- 29 Dec 2014
- Start date
- Apr 2014
- Primary completion date
- Oct 2025
- Lead sponsor
- University of Pisa
- Diseases
- Metastatic breast cancer
- NCT number
- NCT02329639
What you commit to
- Study type: Observational
- Participants enrolled: 307
- From Apr 2014 to the primary completion date, Oct 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- histologically not confirmed HER2-negative MBC, and patients not treated with a first-line chemotherapy with or without bevacizumab.
Who the study is looking for
- histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1,8 and 15,every 4 weeks, will be enrolled for the present pharmacogenetic study. MBC patients treated with a first-line chemotherapy without bevacizumab will also be enrolled as control goup.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Clinical and Experimental Medicine, University of Pisa Coordinator of this site? Confirm its status | Pisa | Italy | Unknown status |
| Azienda USL 5 of Pisa Coordinator of this site? Confirm its status | Pontedera | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.